The clinical application of port A Cath in the hematology-oncology patients

The use of vascular access devices (VADs) is an integral aspect of health care for neonates, children, and adults and has moved beyond the acute care setting to chronic, long-term care. VADs have a paramount role throughout the management of the oncology patient, as they are needed in the initial phases for surgery or chemotherapy, in the advanced stages for chronic treatment, and in the last stages for palliative measures. In patients with cancer, chemotherapeutic drugs can damage the wall of peripheral veins thereby rapidly putting an end to the peripheral access. Central venous lines (CVLs) were first described by Dudrick in 1968. In 1973, the first long-term central venous catheter (CVC) was used for parenteral nutrition. In 1979, the Hickman catheter, a long-term venous access device, was used for chemotherapy for the first time. The introduction of totally implantable port systems started in the early 1980s. In this article, we will review the use of port A Cath and its role in hematology-oncology patients based on the literature review. This article was provided based of review of many recent anf up-to-date articles in field of port A Cath uding and its role in hematology-oncology patients. Evaluation these articles showed the essential role of port A Cath and the best ways to deal with the possible complications. Review of articles revealed the essential role of port A Cath in hematology-oncology patients. Also it is necessary to be careful about using and care of port A Cath.